© 2024 HSP News Service, L.L.C.
Elizabeth H. Phillips, MD, of the University of Manchester and The Christie Hospital, discusses phase II findings showing inotuzumab ozogamicin plus rituximab, cyclophosphamide, vincristine, and prednisolone is a feasible and effective regimen for front-line treatment of high-risk patients with diffuse large B-cell lymphoma who are not eligible for standard chemotherapy (Abstract S232).
John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, discusses the mature results of a phase II study showing durable remissions and long-term tolerability of acalabrutinib in treatment-naive patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (Abstract S163).
In a study reported in JAMA Oncology, Ghosh et al found that a more intense reduced-intensity conditioning and nonmyeloablative conditioning (RIC-NMAC) regimen consisting of fludarabine plus melphalan at 140 mg/kg (Flu-Mel14) appears to be associated with poorer overall survival and higher...
Treatment with the anti–PD-1 agent pembrolizumab significantly improved progression-free survival in patients with classical Hodgkin lymphoma compared with standard brentuximab vedotin, according to results of the phase III KEYNOTE-204.1 The study results were presented during the ASCO20 Virtual...
Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings that showed venetoclax and navitoclax with chemotherapy is well tolerated, with promising efficacy in heavily pretreated patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Clinical follow-up, correlative biomarker analysis, and expansion cohort enrollment to assess discontinuous dosing are underway (Abstract S116).
Michael J. Dickinson, MBBS, DMedSc, of the Peter MacCallum Cancer Centre, discusses phase I dose-escalation study results on CD20-TCB, which showed activity, including durable complete responses, and manageable safety in heavily pretreated patients with relapsed or refractory non-Hodgkin lymphoma (Abstract S241).
In the phase IIb SADAL trial reported in The Lancet Haematology, Kalakonda et al found that the oral nuclear export inhibitor selinexor produced durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma. Findings in the trial supported the recent accelerated U.S. Food...
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to relugolix for the treatment of advanced prostate cancer; Fast Track designation to a radioimmunotherapeutic treatment for marginal zone lymphoma; and Orphan Drug designation to a novel monoclonal antibody for...
In the phase IIb SADAL trial reported in The Lancet Haematology, Kalakonda et al found that the oral nuclear export inhibitor selinexor produced durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma. Findings in the trial supported the recent accelerated U.S. Food...
In a European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group phase III trial reported in The New England Journal of Medicine, Minard‑Colin et al found that the addition of rituximab to standard Lymphomes Malin B (also known as Lymphome Malin de Burkitt, or LMB) chemotherapy ...
Question 1 Which of the following statements about mixed-cellularity classic Hodgkin lymphoma is correct? A. It has a female predominance. B. This type of classic Hodgkin lymphoma is relatively more common in developing nations and is frequently associated with Epstein-Barr virus (EBV) positivity....
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this first-part of a two-part installment, Drs. Abutalib and Medeiros highlight the histologically rare lymphocyte-rich type of classic Hodgkin lymphoma,...
In a recent study reported in the Journal of Clinical Oncology,1 an alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy was found to be highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status. In addition to being...
Harmonization of big data in examining acute and long-term outcomes with contemporary treatment for pediatric and adult patients with Hodgkin lymphoma is yielding a new approach to inform future clinical trial design and enhance clinical decision-making, according to a statement by Rutgers Cancer...
As reported in the Journal of Clinical Oncology by Hayashi et al, the Children’s Oncology Group AALL0434 study has shown “excellent” outcomes with Capizzi-based methotrexate/pegaspargase (C-MTX) treatment in patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma (T-LL). The addition...
On June 22, the U.S. Food and Drug Administration (FDA) approved oral selinexor (Xpovio), a first-in-class, selective inhibitor of nuclear export compound, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified after at least...
Lakshmi Nayak, MD, of Dana-Farber Cancer Institute, reviews two key abstracts on newly diagnosed primary central nervous system lymphoma and treatment with whole-brain radiotherapy, methotrexate, temozolomide, rituximab, procarbazine, vincristine, and cytarabine (Abstracts 2500 and 2501).
Over the past month, the U.S. Food and Drug Administration has granted Fast Track designation to agents designed to treat colorectal and pancreatic cancers, in addition to lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia; accepted a new drug application for a treatment for relapsed or...
Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, explores whether autologous transplantation, in patients with relapsed diffuse large B-cell lymphoma who achieve only a PET/CT-positive partial remission, is appropriate in the era of CAR T-cell therapy (Abstract 8000).
On June 18, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik), an EZH2 inhibitor, for adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have...
In the phase II L-MIND trial reported in The Lancet Oncology, Gilles Salles, MD, and colleagues found that the combination of the Fc-enhanced anti-CD19 monoclonal antibody tafasitamab plus lenalidomide produced responses in patients with relapsed or refractory diffuse large B-cell lymphoma...
Advances in the treatment of hematologic malignancies and some of their associated symptoms were presented during EHA25 Virtual, an ongoing online conference from the European Hematology Association (EHA). Advances in the Treatment of High-Risk CLL: CLL2-GIVe Results In the CLL2-GIVe trial, the...
In a retrospective study reported by Nastoupil et al in the Journal of Clinical Oncology, researchers in the U.S. Lymphoma CAR T Consortium described outcomes with standard-of-care use of the autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel in patients ...
In the fall of 2015, I was looking forward to a trip to Florida for a visit with my daughter and her family, along with a little relaxation. The evening before the trip, I experienced some abdominal pain that my wife, Angela, and I thought might be appendicitis. Concerned the problem could...
In a phase II study reported in the Journal of Clinical Oncology, Roschewski et al found that risk-adapted dose-adjusted etoposide doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (EPOCH-R) produced high event-free survival rates among high- and low-risk adult patients with...
The successful treatment of malignant lymphoma has been one of the great achievements in medical oncology, but certainly more work is needed to define key biologic targets as well as molecular markers for a more accurate definition of prognosis following therapy. In day-to-day practice, unanswered...
In a single-institution retrospective study reported in JCO Oncology Practice, Lynch et al found that routine laboratory surveillance testing had limited value in detecting relapse in patients with classical Hodgkin lymphoma in first remission. Study Details The study involved 235 patients at...
In a phase II German Hodgkin Study Group trial (NIVAHL) reported in JAMA Oncology, Bröckelmann et al found that both concomitant and sequential nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) regimens showed efficacy in first-line treatment of early-stage unfavorable classical...
The 2019 American Society of Hematology (ASH) Annual Meeting & Exposition featured a cornucopia of sessions. It was impossible to attend all the lectures, symposia, oral presentations, poster presentations, and special events because many were concurrent. Below, we have selected some...
Basem M. William, MD, MRCP (UK), FACP, Director of the T-Cell Lymphoma Program and Member of the Blood and Marrow Transplant Program at The Ohio State University Comprehensive Cancer Center, Columbus, said many of the new-generation bispecific antibodies are “highly promising.” He said they “are...
Studies of second-generation bispecific antibodies were among the highlights of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition. The bispecific T-cell engager blinatumomab was the first such agent to be approved by the U.S. Food and Drug Administration (FDA) in...
Are you proceeding with front-line autologous transplant in patients with mantle cell lymphoma or delaying it during the COVID-19 pandemic? Recorded April 21, 2020.
For community oncologists treating patients with non-Hodgkin lymphoma during the COVID-19 pandemic, what resources and clinical pearls would you suggest? Recorded April 21, 2020.
During the COVID-19 pandemic, would you still recommend immediate upfront autologous transplant in patients with T-cell non-Hodgkin lymphoma? Recorded April 21, 2020.
During the COVID-19 pandemic, when and why would you consider delaying autologous transplant for patients with diffuse large B-cell lymphoma in second complete remission? Recorded April 21, 2020.
Are you testing for COVID-19 before administering therapy on an outpatient basis for patients with non-Hodgkin lymphoma? Recorded April 21, 2020.
Over the past 2 weeks, the U.S. Food and Drug Administration (FDA) granted Priority Review to a treatment for acute myeloid leukemia (AML); Fast Track designations for agents in pancreatic cancer and pancreatic/nonpancreatic neuroendocrine tumors; approvals for companion diagnostic tests;...
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for patients with non-Hodgkin lymphomas (NHLs). For full...
The lymphomas are an incredibly complex assemblage of neoplastic diseases. They are not one disease, and, at least based on the World Health Organization (WHO) Classification of Tumors published in 2017, they represent a collection of approximately 80 different malignancies, a number that will...
Vitamin D is a steroid-like hormone involved primarily in human calcium homeostasis. Obtained through sun exposure as well as food and dietary supplements,1 vitamin D in humans is metabolized in the liver and kidneys to its active form, 1,25-dihydroxyvitamin D (1,25[OH]2D).2 Other cell types,...
On April 21, the U.S. Food and Drug Administration (FDA) expanded the indication of ibrutinib (Imbruvica) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This review was conducted...
In a phase II trial reported in The New England Journal of Medicine, Michael Wang, MD, and colleagues found that the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy KTE-X19 produced a high response rate in patients with relapsed or refractory mantle cell lymphoma who had received previous...
The U.S. Food and Drug Administration (FDA) recently approved a new dose for a biosimilar referencing trastuzumab and granted Fast Track designations to agents for patients with urothelial cancer and follicular lymphoma. Approval of Multidose Vial of Trastuzumab Biosimilar The FDA approved a...
ABSTRACT 355: MURANO study: Four-year analysis confirms sustained benefit (compared to bendamustine and rituximab; n = 195) of time-limited venetoclax/rituximab (n = 194) in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; ClinicalTrials.gov NCT02005471)1...
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed chronic lymphocytic leukemia (CLL) and...
In the phase I/II ADVL1412 study reported in The Lancet Oncology, Davis et al identified the phase II dosage of nivolumab monotherapy in children and young adults with relapsed or refractory solid tumors or lymphoma. Objective responses were observed in patients with lymphoma, but not in those with ...
Dr. Armitage discusses the role of CAR T-cell therapy in the management of multiple myeloma and lymphoma in a conversation with his colleagues Dr. Holstein and Dr. Lunning.
Dr. Armitage presents a case and asks Dr. Lunning to describe how he would treat this patient. The patient is a 52-year-old man who found a neck mass himself. He went to his doctor and was prescribed antibiotics. When the antibiotics failed to impact the mass, a biopsy was performed and a diagnosis of diffuse large B-cell lymphoma was made. A positron emission tomography (PET) scan was positive in the neck, mediastinum, axilla, and retroperitoneum. The maximum standardized uptake (SUV) value was 29. A bone marrow biopsy was negative and the patient’s LDH level was slightly above normal. The patient was treated with six cycles of CHOP-R and responded to therapy. Nine months later this individual identified a new node in his neck. He returned to his doctor and a biopsy was performed. A diagnosis of large B-cell lymphoma was made. A PET scan showed disease in the neck and mediastinum, and the maximum SUV is now 18. How would Dr. Lunning approach such a person?
Dr. Armitage presents a case and asks Dr. Lunning to describe how he would treat this patient. The patient is a 25-year-old man with a diagnosis of stage III nodular sclerosing Hodgkin lymphoma. His disease went into complete remission when the patient was treated with ABVD and he was well. One year after his last cycle of therapy, the patient returns to see you, and you detect a node in his neck. A PET scan is performed, showing there is no node larger than 2 cm, but these nodes were present both above and below the diaphragm. The standardized uptake value (SUV) maximum was 8. The lymph node biopsy reveals recurrent lymphoma. What will Dr. Lunning tell this patient?
Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to a combination therapy in diffuse large B-cell lymphoma (DLBCL); gave Fast Track designations for treatments in T-cell lymphoma and adenoid cystic carcinoma; granted Orphan Drug designation to an agent for the ...